AGENUS INC. (NASDAQ:AGEN) Files An 8-K Results of Operations and Financial Condition
The following exhibit is furnished herewith:
|99.1||Press Release dated November 4, 2019|
AGENUS INC Exhibit
EX-99.1 2 tv531603_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Agenus Provides Corporate Update with Third Quarter 2019 Financial Results - PD-1 plus CTLA-4 cervical trial completes planned accrual & planned interim analysis - PD-1 cervical trial on track to complete accrual & planned interim analysis by year-end - Four novel I-O antibodies clear INDs & advance into clinical trials - NexGen CTLA-4 (AGEN1181) advances to 3rd cohort; combo with AGEN2034 to start - $22.5M in cash milestones received as novel antibodies move to clinic - GSK's Shingrix sales >$1Bn,…
To view the full exhibit click
About AGENUS INC. (NASDAQ:AGEN)
Agenus Inc. (Agenus) is an immuno-oncology company. The Company is engaged in discovering and developing treatments for patients with cancer. Its approaches are driven by platforms and programs, which include antibody discovery platform, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage and AutoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in various stages of development, including a series of antibodies in discovery and pre-clinical and clinical development, Prophage vaccine, a Heat Shock Protein (HSP)-based vaccine candidate for a form of brain cancer that has completed Phase II trials, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development.